Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Liabilities and Shareholders Equity (2019 - 2025)

Silence Therapeutics (SLN) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $131.4 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 35.13% to $131.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $628.8 million through Dec 2025, up 210.29% year-over-year, with the annual reading at $131.4 million for FY2025, 35.13% down from the prior year.
  • Liabilities and Shareholders Equity hit $131.4 million in Q4 2025 for Silence Therapeutics, down from $146.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $202.6 million in Q4 2024 to a low of $119.4 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $150.8 million across 5 years, with a median of $139.1 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 69.64% in 2024 and later tumbled 35.13% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $129.7 million in 2021, then fell by 2.76% to $126.1 million in 2022, then decreased by 5.27% to $119.4 million in 2023, then surged by 69.64% to $202.6 million in 2024, then crashed by 35.13% to $131.4 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SLN at $131.4 million in Q4 2025, $146.8 million in Q3 2025, and $165.2 million in Q2 2025.